Literature DB >> 3491129

The effect of benziodarone on the thyroid hormone levels and the pituitary-thyroid axis.

B Xanthopoulos, D A Koutras, M A Boukis, G D Piperingos, J Kitsopanides, A Souvatzoglou, S D Moulopoulos.   

Abstract

The effect of benziodarone on the levels of thyroid hormones in the serum has not attracted interest, in spite of the prolific literature on the related drug amiodarone. It is shown here that benziodarone administration has several effects, mainly similar to amiodarone, but some possibly opposite and inappropriate. Nine normal volunteers received benziodarone, 100 mg three times daily for 14 days. Before and 1, 3, 7 and 14 days after continuous administration the following estimates were obtained: serum T4, T3, rT3 and TSH, both basal (TSH0) and 30 min after iv administration of TRH (TSH30), the difference being calculated as delta TSH. Serum T4 remained relatively constant. Serum T3 decreased significantly from the 1st to the 14th day (eg. before 2.15 +/- 0.12 nmol/l, at 3 days 1.45 +/- 0.07). Serum rT3 increased significantly from the 1st to the 14th day (eg. before 0.71 +/- 0.16 nmol/l, at 7 days 2.61 +/- 0.19). Serum TSH0 and TSH30 decreased significantly on the 1st and 3rd day. Later they increased, and TSH0 at 14 days was significantly higher than the pre-treatment value. Our results suggest that benziodarone has an amiodarone-like action in diverting the peripheral metabolism of T4 towards rT3 rather than T3. However, the effects on the pituitary-thyroid axis are not similar to those previously reported by others and ourselves about amiodarone, and these merit further research.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3491129     DOI: 10.1007/BF03346938

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  16 in total

1.  [Thyrotoxicosis and benzidarone].

Authors:  J P Camus; A Prier; P Kartun
Journal:  Rev Rhum Mal Osteoartic       Date:  1973-02

2.  Relative ineffectiveness of exogenous triiodothyronine as a thyroid suppressive agent.

Authors:  D A Koutras; J Malamitsi; A Souvatzoglou; G D Piperingos; D P Livadas; M Boukis; D N Papachristou; J Sfontouris; S D Moulopoulos
Journal:  J Endocrinol Invest       Date:  1981 Jul-Sep       Impact factor: 4.256

3.  Does amiodarone affect heart rate by inhibiting the intracellular generation of triiodothyronine from thyroxine?

Authors:  M Lindenmeyer; S Spörri; M Stäubli; A Studer; H Studer
Journal:  Br J Pharmacol       Date:  1984-05       Impact factor: 8.739

4.  Effect of amiodarone on serum triiodothyronine, reverse triiodothyronine, thyroxin, and thyrotropin. A drug influencing peripheral metabolism of thyroid hormones.

Authors:  A Burger; D Dinichert; P Nicod; M Jenny; T Lemarchand-Béraud; M B Vallotton
Journal:  J Clin Invest       Date:  1976-08       Impact factor: 14.808

5.  Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy.

Authors:  K Nademanee; B N Singh; J A Hendrickson; A W Reed; S Melmed; J Hershman
Journal:  Circulation       Date:  1982-07       Impact factor: 29.690

6.  Inhibition of intrapituitary thyroxine to 3.5.3'-triiodothyronine conversion prevents the acute suppression of thyrotropin release by thyroxine in hypothyroid rats.

Authors:  P R Larsen; T E Dick; B P Markovitz; M M Kaplan; T G Gard
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

7.  Pharmacokinetics of amiodarone after intravenous and oral administration.

Authors:  M Anastasiou-Nana; G M Levis; S Moulopoulos
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1982-11

8.  The correlation of serum amiodarone levels with abnormalities in the metabolism of thyroxine.

Authors:  M Anastasiou-Nana; D A Koutras; G Levis; A Souvatzoglou; M A Boukis; S D Moulopoulos
Journal:  J Endocrinol Invest       Date:  1984-08       Impact factor: 4.256

9.  Metabolic insufficiency as a limiting factor in the dietetic treatment of obesity.

Authors:  J Kitsopanides; D A Koutras; A Souvatzoglou; M Boukis; G D Piperingos; J Sfontouris; S D Moulopoulos
Journal:  Horm Metab Res       Date:  1981-09       Impact factor: 2.936

10.  Hyperthyroxinemia with bradycardia and normal thyrotropin secretion after chronic amiodarone administration.

Authors:  S Melmed; K Nademanee; A W Reed; J A Hendrickson; B N Singh; J M Hershman
Journal:  J Clin Endocrinol Metab       Date:  1981-11       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.